Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Blood and Marrow Transplant Program, Hematology and Medical Oncology, Taussig Cancer Institute, 9500 Euclid Ave CA60, Cleveland, OH, 44195, USA.
Curr Treat Options Oncol. 2024 Aug;25(8):1027-1037. doi: 10.1007/s11864-024-01240-1. Epub 2024 Jul 25.
Cardiac dysfunction is a serious adverse effect of cancer therapies that can interfere with quality of life and impact long-term survival in patients with cancer. Hematopoietic cell transplantation is a potentially curative therapy for many advanced hematologic malignancies and bone marrow failure syndromes, however is associated with several short- and long-term adverse effects, including importantly, cardiovascular toxicities. The goal of this review article is to describe the cardiovascular events that may develop before, during, and after hematopoietic cell transplantation, review risk factors for short- and long-term cardiovascular toxicities, discuss approaches to cardiovascular risk stratification and evaluation, and highlight the research gaps in the consideration of cardiovascular disease in patients undergoing hematopoietic cell transplantation. Further understanding of cardiovascular events and the factors associated with cardiovascular disease will hopefully lead to novel interventions in managing and mitigating the significant long-term burden of late cardiovascular effects in transplant survivors.
心脏功能障碍是癌症治疗的一种严重不良反应，可影响癌症患者的生活质量并影响其长期生存。造血干细胞移植是许多晚期血液恶性肿瘤和骨髓衰竭综合征的潜在治愈性疗法，但与多种短期和长期不良反应相关，包括重要的心血管毒性。本文的目的是描述造血干细胞移植前、中、后可能发生的心血管事件，回顾短期和长期心血管毒性的危险因素，讨论心血管风险分层和评估的方法，并强调在考虑接受造血干细胞移植的患者的心血管疾病时存在的研究空白。进一步了解心血管事件和与心血管疾病相关的因素，有望为管理和减轻移植幸存者晚期心血管影响的巨大长期负担提供新的干预措施。
